CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Baker Chad R

Baker Chad R lowered its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 6.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 93,205 shares of the company’s stock after selling 6,075 shares during the period. Baker Chad R’s holdings in CRISPR Therapeutics were worth $3,669,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Choreo LLC purchased a new position in shares of CRISPR Therapeutics during the 2nd quarter valued at approximately $218,000. American Century Companies Inc. lifted its holdings in CRISPR Therapeutics by 4.0% during the second quarter. American Century Companies Inc. now owns 18,411 shares of the company’s stock valued at $994,000 after purchasing an additional 703 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of CRISPR Therapeutics by 2.1% in the second quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock valued at $51,326,000 after purchasing an additional 19,094 shares during the period. Mercer Global Advisors Inc. ADV increased its stake in shares of CRISPR Therapeutics by 4.3% during the second quarter. Mercer Global Advisors Inc. ADV now owns 10,787 shares of the company’s stock worth $583,000 after purchasing an additional 447 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its position in shares of CRISPR Therapeutics by 13.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 4,167 shares of the company’s stock worth $225,000 after purchasing an additional 486 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Stock Up 0.6 %

Shares of CRISPR Therapeutics stock opened at $40.53 on Friday. The firm has a market cap of $3.46 billion, a PE ratio of -14.32 and a beta of 1.68. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $91.10. The business’s fifty day simple moving average is $45.01 and its 200-day simple moving average is $48.16.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. The business had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period last year, the business earned ($1.41) earnings per share. As a group, equities analysts expect that CRISPR Therapeutics AG will post -5.13 earnings per share for the current year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares of the company’s stock, valued at $10,002,854. The trade was a 7.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.10% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on CRSP shares. Royal Bank of Canada reiterated a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Needham & Company LLC reiterated a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday. Bank of America reduced their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. JMP Securities reaffirmed a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a report on Friday, December 20th. Finally, Barclays reduced their target price on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $78.38.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.